|
|
|
||||||||||
Associate Clinical Professor, Department of Clinical Pharmacy Practice, College of Pharmacy and Allied Health Professions, St. John's University, Queens, NY; Clinical Coordinator, Pediatric Pharmacy Services, Department of Pharmacy, Schneider Children's Hospital, New Hyde Park, NY
Assistant Clinical Professor, Department of Clinical Pharmacy Practice, Collegee of Pharmacy and Allied Health Professions, St. John's University; Assistant Director, Drug Information Services, Department of Pharmacy, Long Island Jewish Medical Center, New Hyde Park
Associate Clinical Professor, Department of Clinical Pharmacy Practice, College of Pharmacy and Allied Health Professions, St. John's University; Director, Drug Information Services, Department of Pharmacy, Long Island Jewish Medical Center
Assistant Clinical Professor, Department of Clinical Pharmacy Practice, College of Pharmacy and Allied Health Professions, St. John's University; Clinical Coordinator, Psychiatric Pharmacy, Zucker Hillside Hospital, North Shore-Long Island Jewish Health System, Glen Oaks, NY
Reprints: Dr. Gianni Augusto, St. John's University, Clinical Pharmacy Practice Department, SAH Rm. 114, 8000 Utopia Pkwy., Queens, NY 11439-0001, fax 718/990-1986, giannil{at}stjohns.edu
OBJECTIVE: To review the efficacy and safety of naltrexone in pediatric patients with autistic disorder (AD).
DATA SOURCES: Using the terms pediatric, child, naltrexone, autism, and autistic disorder, a literature search was performed using MEDLINE (1966-May 18, 2006) and the International Pharmaceutical Abstracts (1971-May 18, 2006) database. The references of these articles were scanned for additional relevant literature.
STUDY SELECTION AND DATA EXTRACTION: All articles describing or evaluating the efficacy and/or safety of naltrexone in pediatric patients with AD were included in this review. Three case reports, 8 case series, and 14 clinical studies were identified as pertinent.
DATA SYNTHESIS: Naltrexone has been used most commonly at doses ranging from 0.5 to 2 mg/kg/day and found to be predominantly effective in decreasing self-injurious behavior. Naltrexone may also attenuate hyperactivity, agitation, irritability, temper tantrums, social withdrawal, and stereotyped behaviors. Patients may also exhibit improved attention and eye contact. Transient sedation was the most commonly reported adverse event. Small sample size, short duration, and inconsistent evaluative methods characterize the available research.
CONCLUSIONS: A child affected by AD may benefit from a trial of naltrexone therapy, particularly if the child exhibits self-injurious behavior and other attempted therapies have failed. Serious adverse effects have not been reported in short-term studies.
Key Words: autism, autistic disorder, naltrexone, pediatrics
Published Online, May 30, 2006. www.theannals.com, DOI 10.1345/aph.1G499
This article has been cited by other articles:
![]() |
A. Stefanatou Use of drawings in children with pervasive developmental disorder during hospitalization: a developmental perspective J Child Health Care, December 1, 2008; 12(4): 268 - 283. [Abstract] [PDF] |
||||
![]() |
N. C Brahm, G. A Fast, and R. C Brown Buspirone for Autistic Disorder in a Woman with an Intellectual Disability Ann. Pharmacother., January 1, 2008; 42(1): 131 - 137. [Abstract] [Full Text] [PDF] |
||||